Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

360 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-16

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Evolution and Prognosis of Moyamoya Disease

NCT05619068

Moyamoya Disease Revascularization Cognitive Impairment +1 more

RECRUITING

Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease

NCT06925178

Cerebrovascular Disease

RECRUITING

Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia

NCT06041659

Moyamoya Disease

RECRUITING

The Role of m6A RNA Modification in Moyamoya Disease

NCT04696094

Moyamoya Disease

UNKNOWN

Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia

NCT06534658

Alzheimer Disease Image

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. Due to the long-term low perfusion state of brain tissue, most patients with MMD experience varying degrees of cognitive dysfunction, although the underlying mechanisms remain unclear. We will employ a combination of 256-lead high-density electroencephalography, multimodal magnetic resonance imaging, and biological samples to conduct a comprehensive evaluation of the risk factors associated with cognitive decline in patients with MMD. Our objectives include identifying target imaging areas indicative of cognitive damage in the brain and exploring the structural and functional changes in the cerebral network resulting from revascularization, as well as their relationship with cognitive improvement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moyamoya Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Revascularization

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.
* Please sign the informed consent form.
* Participants must be between 18 and 60 years of age.

Exclusion Criteria

* Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome.
* Individuals younger than 18 years or older than 60 years.
* Those with contraindications for magnetic resonance imaging.
* Patients who are unable to complete cognitive brain assessments

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes